Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.

Castration Resistant ◽

Prognostic And Predictive Factors

Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2016.06.010 ◽

2017 ◽

Vol 15 (2) ◽

pp. 313-319 ◽

Cited By ~ 16

Author(s):

Hideaki Miyake ◽

Takuto Hara ◽

Tomoaki Terakawa ◽

Seiichiro Ozono ◽

Masato Fujisawa

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Clinical Outcomes ◽

Real World ◽

Abiraterone Acetate ◽

Comparative Assessment ◽

Castration Resistant ◽

Cancer Experience

Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer

Anticancer Research ◽

10.21873/anticanres.12702 ◽

2018 ◽

Vol 38 (7) ◽

pp. 4115-4121 ◽

Cited By ~ 2

Author(s):

TOMOHIKO MURAKAMI ◽

HIROFUMI OBATA ◽

NAOKO AKITAKE ◽

MASAKI SHIOTA ◽

ARIO TAKEUCHI ◽

...

Keyword(s):

Prostate Cancer ◽

Predictive Factors ◽

Castration Resistant ◽

Androgen Withdrawal ◽

Prognostic And Predictive Factors

Enzalutamide (E) vs abiraterone acetate (AA) in the treatment of metastatic, castration-resistant prostate cancer. Indirect comparisons and network meta-analysis for clinical practice

Annals of Oncology ◽

10.1093/annonc/mdx423.011 ◽

2017 ◽

Vol 28 ◽

pp. vi20

Author(s):

E. Bianchi ◽

M. Fantini ◽

S.L.V. Nicoletti ◽

F. Drudi ◽

E. Tamburini ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Indirect Comparisons

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice

European Urology Focus ◽

10.1016/j.euf.2016.02.013 ◽

2016 ◽

Vol 2 (5) ◽

pp. 540-546 ◽

Cited By ~ 15

Author(s):

Mariana Reza ◽

Mattias Ohlsson ◽

Reza Kaboteh ◽

Aseem Anand ◽

Ingela Franck-Lissbrant ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Multicentre Study ◽

Bone Scan ◽

Abiraterone Acetate ◽

Imaging Biomarker ◽

Bone Scan Index ◽

P091 Analysis of predictive factors of response and survival in castration-resistant prostate cancer treated with abiraterone acetate

European Urology Supplements ◽

10.1016/s1569-9056(14)61314-2 ◽

2014 ◽

Vol 13 (5) ◽

pp. 144

Author(s):

P. Beardo Villar ◽

C. Baena Villamarín ◽

L. Gambra Arregui ◽

M.J. Ledó Cepero ◽

J. Soto Villalba ◽

...

Keyword(s):

Prostate Cancer ◽

Predictive Factors ◽

Abiraterone Acetate ◽

2565 QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice

European Journal of Cancer ◽

10.1016/s0959-8049(16)31384-3 ◽

2015 ◽

Vol 51 ◽

pp. S499

Author(s):

R.D. Hofheinz ◽

S.E. Al-Batran ◽

C. Windemuth-Kieselbach ◽

P. Hammerer

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Clinical Practice ◽

Daily Clinical Practice ◽

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

Case Medical Research ◽

10.31525/ct1-nct04232761 ◽

2020 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Alpha Particle ◽

Routine Clinical Practice ◽

Castration Resistant ◽

Radium 223

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽